Holdings
Vestal Point Capital, LP
As of Sep 30, 2026, Vestal Point Capital, LP reported 55 positions worth US$3.58B. Largest: Abivax SA, Neurocrine Biosciences, Inc. and BioMarin Pharmaceutical Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Abivax SA | 3.96M | US$392M | +1.61M | Sep 30, 2026 |
| Neurocrine Biosciences, Inc. | 2.5M | US$355M | +620K | Sep 30, 2026 |
| BioMarin Pharmaceutical Inc. | 5.53M | US$332M | −500K | Sep 30, 2026 |
| Arrowhead Pharmaceuticals, Inc. | 4.82M | US$315M | +3.24M | Sep 30, 2026 |
| Insmed Incorporated | 2.73M | US$311M | +2.48M | Sep 30, 2026 |
| United Therapeutics Corporation | 475K | US$257M | +40,000 | Sep 30, 2026 |
| Nurix Therapeutics, Inc. | 7.03M | US$167M | −1.02M | Sep 30, 2026 |
| Tarsus Pharmaceuticals, Inc. | 2.03M | US$160M | +984K | Sep 30, 2026 |
| Enliven Therapeutics, Inc. | 3.23M | US$148M | −775K | Sep 30, 2026 |
| Disc Medicine, Inc. | 1.64M | US$107M | +85,000 | Sep 30, 2026 |